Short Interest in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY) Expands By 67.4%

Key Points

• Short interest in Otsuka Holdings Co., Ltd. increased by 67.4% in August, rising to 14,900 shares from 8,900 shares at the end of July.
• The stock price of Otsuka rose 2.7% to $28.25, with a trading volume of 80,356 shares compared to its average of 30,509 shares.
• Analysts have given Otsuka a consensus "Sell" rating, with Zacks Research specifically upgrading it to a "strong sell" rating on August 11th.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 14,900 shares, anincreaseof67.4% from the July 31st total of 8,900 shares. Based on an average daily trading volume, of 72,900 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 72,900 shares, the short-interest ratio is currently 0.2 days.

Otsuka Stock Up 2.7%

OTSKY traded up $0.74 during midday trading on Friday, hitting $28.25. The company had a trading volume of 80,356 shares, compared to its average volume of 30,509. Otsuka has a 52 week low of $21.64 and a 52 week high of $32.41. The company has a market capitalization of $30.35 billion and a price-to-earnings ratio of 0.19. The stock's 50 day moving average price is $24.95 and its 200 day moving average price is $24.76.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Otsuka to a "strong sell" rating in a report on Monday, August 11th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of "Sell".

About Otsuka

Otsuka Holdings Co, Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.